Colestipol is an antihyperlipidemic drug approved by the United States Food and Drug Administration (FDA) as an adjunctive therapy to lower elevated low-density lipoprotein cholesterol in patients with primary hypercholesterolemia unresponsive to dietary modifications alone. The drug can be used as monotherapy or in conjunction with a statin, niacin, or ezetimibe. Colestipol is a cholesterol-lowering drug that reduces the risk of coronary artery disease. This drug belongs to the class of bile acid sequestrants and is one of the earliest drugs used for this purpose. However, the current predominant application involves providing supplementary therapy, especially in cases where statins or alternative lipid-lowering agents prove inadequate in sufficiently reducing cholesterol levels.
Copyright © 2024, StatPearls Publishing LLC.